TB policies in 29 Countries
A survey of prevention, testing and treatment policies and practices
Health Evidence Network synthesis report 53
Blueprint for EECA countries, first edition
Rapport sur les populations clès
Accessed November 2017
Key populations brief
Accessed 2017
Informe sobre poblaciones clave
Global Plan to end TB 2016-2020
Key populations brief
Accessed November 2017
Ensuring Access to Simple, Safe and Effective First-Line Medicines for Tuberculosis.
Accessed in November 2017.
A compendium of TB REACH case studies, lessons learned and a monitoring and evaluation framework.
Accessed November 2017.
A review of available evidence (2016).
28-29 June 2016; Geneva, Switzerland
The END TB strategy.
Report: A survey conducted among the 27 high MDR-TB burden countries.
March – July 2015
Stop TB Partnership in collaboration with Medecins Sans Frontieres (MSF).
Accessed November 2017.
3rd Edition – July 2017
www.msfaccess.org
Direct acting antivirals (DAAs) have revolutionized treatment for hepatitis C. Combi-
nations of DAAs can cure infection with HCV in 12 weeks, are highly effective and
have limited side-effects. Affordability of DAAs has improved significantly, but access remains lim-
i...ted. Initially, due to their high prices, affordability of DAAs was limited in high-, middle- and low-
income countries alike. Now there is a divide between those countries where, because of intellectual
property barriers, prices have remained (very) high and other countries where generics are, or can be,
available at much lower prices. The result is a dual market
more
Practical Guidance for collaborative interventions
Guidelines for treatment of drug-susceptible tuberculosisand patient care
2017 Update